TORONTO, ON / ACCESSWIRE / December 15, 2015 / Theralase Technologies Inc. ("Theralase" or the "Company") (TLT:TSXV) (TLTFF:OTC), a leading biotechnology manufacturer focused on commercializing medical technologies to eliminate pain and destroy cancer, announced today that it has commenced launch of its next generation therapeutic laser, the TLC-2000 Therapeutic Medical Laser System, in Canada.
The Canadian market represents over 128,000 healthcare practitioners, with the ability to purchase the TLC-2000, for their respective clinical practices.
David Smith, Director of Global Sales stated, "Health Canada approval of the TLC-2000 is a major accomplishment for the Company, allowing our sales team the ability to sell the safest and most effective therapeutic laser system ever designed to the Canadian healthcare market. Canada has the largest installed base of Theralase products, with approximately 800 installations and based on the performance of this next generation technology, I expect a high "trade-up" rate to the latest next generation technology. Now that Health Canada approval has been received, Theralase can execute on its strategic objective of increasing the revenue of the Company into the many millions of dollars commencing in 2016. The Company possesses the strategic plan, the personnel and the capital with which to execute on this objective."
Roger Dumoulin-White, President and CEO, stated that, "The Company has now completed two out of four of its key 2015 strategic objectives; specifically, FDA and Health Canada approval of its next generation TLC-2000 technology. Theralase is now well positioned to execute on generating significant revenue for the Company, by introducing this state-of-the-art technology to approximately 1.5 million healthcare practitioners located throughout Canada and the US, commencing in 2016. The remaining two strategic objectives involve Health Canada (Clinical Trial Application and Investigational Testing Authorization) and University Health Network (Review Ethics Board) approval of the Company's anti-cancer Photo Dynamic Therapy technology allowing commencement of a Phase Ib clinical trial to prove safety, tolerability and as an exploratory end point, efficacy, in a patient population diagnosed with high grade Non-Muscle Invasive Bladder Cancer that has failed standard of care."
About Theralase Technologies Inc.
Theralase Technologies Inc. ("Theralase(R)") (TSXV: TLT) (TLTFF: OTC) in its Therapeutic Laser Technology Division designs, manufactures and markets patented super-pulsed laser technology indicated for the: elimination of pain, reduction of inflammation and dramatic acceleration of tissue healing for numerous nerve, muscle and joint conditions. Theralase's Photo Dynamic Therapy Division researches and develops specially designed molecules called Photo Dynamic Compounds, which are able to localize to cancer cells and then when laser light activated, effectively destroy them.
Theralase Technologies Inc. was recognized as a TSX Venture 50(R) company in 2015. TSX Venture 50 is a trademark of TSX Inc. and is used under license.
This press release contains forward-looking statements, which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual results could differ materially from those projected herein. The Company disclaims any obligation to update these forward-looking statements.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchanges) accepts responsibility for the adequacy or accuracy of this release.
For More Information:
SOURCE: Theralase Technologies Inc.